Joseph Ray
Clinical Genetics (M.D.) · Galveston, TXNPI 1083960884
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $425,362 of the $642,184 with a category attached, or 66.2%. Sanofi accounts for 62.8% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $190,374, 2.9 times the $65,891 reported in 2019. Among clinical genetics (m.d.) clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 693 payments — averaging $926.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$403K
- Biomarin Pharmaceutical Inc.$116K
- Mirum Pharmaceuticals, Inc.$83K
- PTC Therapeutics, Inc.$16K
- Sarepta Therapeutics, Inc.$6K
- Chiesi USA, Inc.$6K
- plus $12K from 12 others
What the payments were for
- Consulting fees$95,55715%
- Speaking & faculty fees$425,36266%
- Travel & lodging$105,56216%
- Food & beverage$14,8352%
- Education$8680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 379 | $403,306 |
| Biomarin Pharmaceutical Inc. | 169 | $115,753 |
| Mirum Pharmaceuticals, Inc. | 77 | $82,559 |
| PTC Therapeutics, Inc. | 21 | $16,469 |
| Sarepta Therapeutics, Inc. | 14 | $6,312 |
| Chiesi USA, Inc. | 7 | $6,177 |
| Travere Therapeutics, Inc. | 6 | $5,346 |
| Amicus Therapeutics, Inc. | 2 | $3,036 |
| ITF Therapeutics LLC | 2 | $2,650 |
| Novartis | 2 | $209 |
| Ultragenyx Pharmaceutical Inc. | 5 | $154 |
| AstraZeneca | 2 | $67 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Cycle Pharmaceuticals Inc | 1 | $26 |
| Shire North American Group Inc | 1 | $24 |
| Sanofi US Services Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Pharming Healthcare, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$238,516
- CERDELGA$118,013
- CEREZYME$106,603
- Palynziq$82,660
- (820) Cholbam$75,502
- LUMIZYME$48,325
- Kuvan$31,619
- NEXVIAZYME$29,693
- CTEXLI$24,478
- ALDURAZYME$22,865
- (810) Chenodal$13,273
- Livmarli$9,572
- EMFLAZA$6,567
- VOXZOGO 1.2mg$3,401
- GALAFOLD$3,000
- FERRIPROX$1,200
- NO PRODUCT DISCUSSED$867
- ELFABRIO$450
- ZOLGENSMA$182
- SEPHIENCE$175
How this compares
$642,184 in reported general payments places this provider in the 95th percentile of 37 clinical genetics (m.d.) providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PalynziqPegvaliase-Pqpz | 26 | $1,228,021 |
| FabrazymeAgalsidase Beta | 25 | $346,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biomarin Pharmaceutical Inc.Palynziq | $115,753 | $1,228,02126 claims |
| SanofiFabrazyme | $403,306 | $346,13625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 37 clinical genetics (m.d.) providers in Texas.
Other clinical genetics (m.d.) in Galveston
- Joseph GoldsteinDallas$5.5M
- Markey McNuttDallas$247K
- Hope NorthrupHouston$180K
- Paul HillmanHouston$68K
- Erin CooneyLeague City$44K
- Brendan LeeHouston$28K
- David RodriguezHouston$28K
- Fernando ScagliaHouston$16K
- Candace GambleFort Worth$5K
- Taylor TeagueTyler$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.